Related Experiment Videos
Functional evaluation of the apoptosome in renal cell carcinoma
M C Gerhard1, N Zantl, G Weirich
1Institute for Medical Microbiology, Immunology and Hygiene, Trogerstrasse 9, Munich D-81675, Germany.
Abstract:
Renal cell carcinoma (RCC) responds very poorly to chemo- or radiotherapy. Renal cell carcinoma cell lines have been described to be resistant to apoptosis-inducing stimuli and to lack caspase expression. Here, we provide a structural and functional assessment of the apoptosome, the central caspase-activating signalling complex and a candidate for apoptosis-inactivating mutations. Cells from RCC cell lines and clinical samples isolated from RCC patients were included. Apoptosome function was measured as quantitative activation of caspases in protein extracts. In all five cell lines and in 19 out of 20 primary clear cell RCC samples, the expression of apoptosome components and caspase activation appeared normal. Of the four nonclear cell RCC that could be included, both oncocytomas gave no response to cytochrome c (in one case, no Apaf-1 was detected), one chromophobe RCC lacked caspase-9 and failed to activate caspase-3 in response to cytochrome c, and one papillary RCC showed good caspase activation despite the lack of caspase-7. Experiments utilising a peptide derived from Smac/DIABLO gave no indication that inhibitor of apoptosis proteins might exert an inhibiting effect in primary clear cell RCC. Thus, the apoptosome signalling complex is intact in human (clear cell) RCC, and an apoptosis defect must be located at other, probably upstream, sites.
Insights
Renal cell carcinoma (RCC) is resistant to standard treatments. Studies found the apoptosome, a key cell death complex, is intact in most RCC, suggesting defects lie elsewhere.
Area of Science:
- Oncology
- Molecular Biology
- Cell Death Research
Background:
- Renal cell carcinoma (RCC) exhibits resistance to chemotherapy and radiotherapy.
- RCC cell lines are known for resistance to apoptosis and lack of caspase expression.
Purpose of the Study:
- To structurally and functionally assess the apoptosome in renal cell carcinoma.
- To identify potential apoptosis-inactivating mutations within the apoptosome complex in RCC.
Main Methods:
- Analysis of apoptosome components and caspase activation in RCC cell lines and patient samples.
- Quantitative measurement of caspase activation in protein extracts following cytochrome c stimulation.
- Investigation of inhibitor of apoptosis proteins (IAPs) using Smac/DIABLO-derived peptides.
Main Results:
- The apoptosome signaling complex and caspase activation were found to be normal in most clear cell RCC samples (5/5 cell lines, 19/20 primary samples).
- Specific defects were noted in non-clear cell RCC subtypes, including absent Apaf-1 in one oncocytoma and lack of caspase-9 in one chromophobe RCC.
- No evidence of IAP-mediated inhibition was found in primary clear cell RCC.
Conclusions:
- The apoptosome signaling complex is intact in human clear cell renal cell carcinoma.
- Apoptosis defects in clear cell RCC are likely located upstream of the apoptosome complex.